Serum endocan levels in non-ST segment elevation myocardial infarction patients - Takeaways - MDSpire

Serum endocan levels in non-ST segment elevation myocardial infarction patients

  • By

  • Adem Melekoglu

  • Alp Giray Aydin

  • Uğur Kahveci

  • Nazmiye Ozcan

  • Serkan Ceritli

  • Zeynep Mine Yalcinkaya Kara

  • Hakan Kilci

  • Ertugrul Altinbilek

  • Derya Ozturk

  • June 3, 2026

  • 0 min

Share

  • 1

    Serum endocan levels are significantly elevated in NSTEMI patients with clinically significant coronary stenosis compared to those with non-significant stenosis.

  • 2

    Endocan is independently associated with the severity of coronary stenosis, alongside BMI and C-reactive protein levels.

  • 3

    The study included 81 NSTEMI patients, with 40 showing clinically significant coronary stenosis and 41 with non-significant stenosis.

  • 4

    Endocan demonstrated good discriminatory ability for identifying clinically significant coronary stenosis, with an AUC of 0.826.

  • 5

    Systemic factors such as age, diabetes, and smoking may contribute to elevated serum endocan levels in NSTEMI patients.

Original Source(s)

Serum endocan levels in non-ST segment elevation myocardial infarction patients

  • by Adem Melekoglu, Alp Giray Aydin, Uğur Kahveci, Nazmiye Ozcan, Serkan Ceritli, Zeynep Mine Yalcinkaya Kara, Hakan Kilci, Ertugrul Altinbilek, Derya Ozturk

  • June 3, 2026

Related Content

Incorrect eTable 9 in Supplement 1

  • June 1, 2026

Monitoring Blood Pressure Outside of Your Doctor’s Office

AI-driven cardiovascular risk prediction in patients with diabetes: bridging algorithmic innovation to equitable clinical application